Chromadex Corp. (CDXC)

4.44
0.01 0.23
NASDAQ : Process Industries
Prev Close 4.43
Open 4.49
Day Low/High 4.42 / 4.53
52 Wk Low/High 2.79 / 5.00
Volume 33.28K
Avg Volume 205.30K
Exchange NASDAQ
Shares Outstanding 46.09M
Market Cap 210.19M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
ChromaDex To Report Second Quarter 2015 Financial Results On Thursday, August 13, 2015

ChromaDex To Report Second Quarter 2015 Financial Results On Thursday, August 13, 2015

Company Will Host Investor Conference Call on Wednesday, August 19, 2015

Nutrition Business Journal Honors ChromaDex With Business Achievement Award For Growth

Nutrition Business Journal Honors ChromaDex With Business Achievement Award For Growth

ChromaDex Has Reported Four Consecutive Quarters of Record Net Revenue and Receives Accolades for Top Growth Company in the $10-$50 Million Annual Sales Category

Healthy Directions Has Launched NRG AdvantageTM Featuring NIAGEN(R)-the World's First And Only Commercially Available Form Of Nicotinamide Riboside (NR)

Healthy Directions Has Launched NRG AdvantageTM Featuring NIAGEN(R)-the World's First And Only Commercially Available Form Of Nicotinamide Riboside (NR)

The New Dietary Supplement Protects Against Oxidative Stress and Promotes Healthy Aging

ChromaDex Announces Exclusive Worldwide License And Supply Agreement For Anthocyanin Rich Suntava(R) Purple Corn

ChromaDex Announces Exclusive Worldwide License And Supply Agreement For Anthocyanin Rich Suntava(R) Purple Corn

ChromaDex Will Use Proprietary Suntava(R) Purple Corn to Produce a Highly Concentrated Anthocyanin Ingredient at a Price Point That Should Appeal to Mass Markets

ChromaDex Reports 1st Quarter Record Revenue As Ingredients Sales Soar 136%

ChromaDex Reports 1st Quarter Record Revenue As Ingredients Sales Soar 136%

- Total Q1 Revenue Grew 71% to $5.3 Million as Company Reports 4th Consecutive Quarter of Record Net Revenue -

ChromaDex To Host First Quarter 2015 Investor Call On Monday, May 18th At 11 Am EDT

ChromaDex To Host First Quarter 2015 Investor Call On Monday, May 18th At 11 Am EDT

Company Will Release First Quarter Earnings Report After Market Close on May 14th

Published Study Shows Topical Treatment With Pterostilbene Effectively Protects Hairless Mice Against UVB Radiation-Induced Skin Damage And Carcinogenesis

Published Study Shows Topical Treatment With Pterostilbene Effectively Protects Hairless Mice Against UVB Radiation-Induced Skin Damage And Carcinogenesis

ChromaDex Holds Exclusive Worldwide Patent Rights Related to Pharmaceutical and Cosmetic Preparations of Pterostilbene for Topical Application

Insiders Trading CDXC, IHS, HFC, MWIV

Insiders Trading CDXC, IHS, HFC, MWIV

The top 10 open-market insider purchases and sales filed at the SEC Thursday.

(Graphic: Business Wire)

(Graphic: Business Wire)

Standard & Poor’s announced today that it has commenced Factual Stock Report coverage on ChromaDex Corporation.

DiscoveryBioMed, Inc. Awarded Phase 1 SBIR Catalyst Grant Under The Recovery Act By The NIH To Discover Anti-Inflammatory Drugs

DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a $200,000 Small Business Innovations Research (SBIR) Phase 1 grant by the National Institutes of Health (NIH) to continue research into the ...

TheStreet Quant Rating: D (Sell)